Global Short Bowel Syndrome Market

Short Bowel Syndrome Comprehensive Study by Type (GLP-2, Growth Hormone, Glutamine, Others), Application (Hospitals, Clinics), Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Others), Patients (Adults, Kids, Geriatric) Players and Region - Global Market Outlook to 2029

Short Bowel Syndrome Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Short Bowel Syndrome
Short bowel syndrome affects the useful capability of the internal organ. Patients suffering from short bowel syndrome have a reduced ability to soak up trace components, fats, vitamins, fluids, minerals, and carbohydrates and may expertise weight loss, malnutrition, diarrhea, and dehydration. Presently, there's no cure for brief bowel syndrome, and also the treatment is targeted towards symptoms. In very few cases, short internal organ syndrome can be life-threatening however sometimes, the diseased bowel managed through effective medication. In most cases, short bowel syndrome is related to bowel surgeries. It's generally acquired over the individual’s lifespan and in barely some cases, it's a genetic incidence. Treatment principally includes nutrition & diet management, medication, and surgery. In medication, teduglutide was 1st approved by the federal agency for brief bowel syndrome disorder. Different treatments embody antidiarrheal, histamine blockers, nucleon pump inhibitors, and growth hormones.

AttributesDetails
Study Period2019-2029
Base Year2023
UnitValue (USD Million)


State governments provide special incentives to manufacturers for the development of short bowel syndrome drugs. The development of short bowel syndrome drugs is at a nascent stage, which creates more opportunities for global players. Public-private partnerships are encouraging pharmaceutical companies to develop new orphan drugs for short bowel syndrome. A few countries have implemented a combination of legislation, regulations, and policies promoting drug development for short bowel syndrome. All these factors act as potential drivers for the growth of the short bowel syndrome market. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Short Bowel Syndrome market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Shire Plc (United States), Merck & Company, Inc. (United States), Swedish Orphan Biovitrum AB (Sweden), Novartis AG (Switzerland), Pfizer Inc. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (United States), AstraZeneca Plc (United Kingdom) and Johnson & Johnson (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Short Bowel Syndrome market by Type (GLP-2, Growth Hormone, Glutamine and Others), Application (Hospitals and Clinics) and Region.



On the basis of geography, the market of Short Bowel Syndrome has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Short Bowel Syndrome market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Patients, the sub-segment i.e. Adults will boost the Short Bowel Syndrome market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Adoption of The Treatment and Increasing Recommendation by The Doctors

Market Growth Drivers:
Raising Awareness and Availability of Epidemiological Data, Rapid Improvements in The Field of Healthcare and A Rise in The Geriatric Population

Challenges:
A Lack of Approved Treatment Options

Restraints:
High Cost of The Treatments

Opportunities:
Non-Profit Organizations Are Promoting Research & Development

Market Leaders and their expansionary development strategies
In June 2022, National Institute for Health and Care Excellence (NICE), the health technology appraisal body in England and Wales recommended the use of Takeda's Revestive (teduglutide) once daily subcutaneous injection as an option for people living with Short Bowel Syndrome (SBS) aged 1 year and above.
In October 2022, VectivBio Holding AG released positive interim data from the company's ongoing Phase 2 study evaluating the safety, pharmacokinetics, and efficacy of apraglutide, a GLP-2 agonist, in adult patients with Short Bowel Syndrome.


Key Target Audience
Providers of Short Bowel Syndrome, Governmental and Regulatory bodies and End-Users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • GLP-2
  • Growth Hormone
  • Glutamine
  • Others
By Application
  • Hospitals
  • Clinics
By Distribution Channel
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Others

By Patients
  • Adults
  • Kids
  • Geriatric

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Raising Awareness and Availability of Epidemiological Data
      • 3.2.2. Rapid Improvements in The Field of Healthcare
      • 3.2.3. A Rise in The Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. A Lack of Approved Treatment Options
    • 3.4. Market Trends
      • 3.4.1. Adoption of The Treatment
      • 3.4.2. Increasing Recommendation by The Doctors
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Short Bowel Syndrome, by Type, Application, Distribution Channel, Patients and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Short Bowel Syndrome (Value)
      • 5.2.1. Global Short Bowel Syndrome by: Type (Value)
        • 5.2.1.1. GLP-2
        • 5.2.1.2. Growth Hormone
        • 5.2.1.3. Glutamine
        • 5.2.1.4. Others
      • 5.2.2. Global Short Bowel Syndrome by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
      • 5.2.3. Global Short Bowel Syndrome by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Specialty Pharmacies
        • 5.2.3.3. Others
      • 5.2.4. Global Short Bowel Syndrome by: Patients (Value)
        • 5.2.4.1. Adults
        • 5.2.4.2. Kids
        • 5.2.4.3. Geriatric
      • 5.2.5. Global Short Bowel Syndrome Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Short Bowel Syndrome: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Shire Plc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Company, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Swedish Orphan Biovitrum AB (Sweden)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mylan N.V. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AstraZeneca Plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Johnson & Johnson (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Short Bowel Syndrome Sale, by Type, Application, Distribution Channel, Patients and Region (value) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Short Bowel Syndrome (Value)
      • 7.2.1. Global Short Bowel Syndrome by: Type (Value)
        • 7.2.1.1. GLP-2
        • 7.2.1.2. Growth Hormone
        • 7.2.1.3. Glutamine
        • 7.2.1.4. Others
      • 7.2.2. Global Short Bowel Syndrome by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
      • 7.2.3. Global Short Bowel Syndrome by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Specialty Pharmacies
        • 7.2.3.3. Others
      • 7.2.4. Global Short Bowel Syndrome by: Patients (Value)
        • 7.2.4.1. Adults
        • 7.2.4.2. Kids
        • 7.2.4.3. Geriatric
      • 7.2.5. Global Short Bowel Syndrome Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Short Bowel Syndrome: by Type(USD Million)
  • Table 2. Short Bowel Syndrome GLP-2 , by Region USD Million (2018-2023)
  • Table 3. Short Bowel Syndrome Growth Hormone , by Region USD Million (2018-2023)
  • Table 4. Short Bowel Syndrome Glutamine , by Region USD Million (2018-2023)
  • Table 5. Short Bowel Syndrome Others , by Region USD Million (2018-2023)
  • Table 6. Short Bowel Syndrome: by Application(USD Million)
  • Table 7. Short Bowel Syndrome Hospitals , by Region USD Million (2018-2023)
  • Table 8. Short Bowel Syndrome Clinics , by Region USD Million (2018-2023)
  • Table 9. Short Bowel Syndrome: by Distribution Channel(USD Million)
  • Table 10. Short Bowel Syndrome Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 11. Short Bowel Syndrome Specialty Pharmacies , by Region USD Million (2018-2023)
  • Table 12. Short Bowel Syndrome Others , by Region USD Million (2018-2023)
  • Table 13. Short Bowel Syndrome: by Patients(USD Million)
  • Table 14. Short Bowel Syndrome Adults , by Region USD Million (2018-2023)
  • Table 15. Short Bowel Syndrome Kids , by Region USD Million (2018-2023)
  • Table 16. Short Bowel Syndrome Geriatric , by Region USD Million (2018-2023)
  • Table 17. South America Short Bowel Syndrome, by Country USD Million (2018-2023)
  • Table 18. South America Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 19. South America Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 20. South America Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 21. South America Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 22. Brazil Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 23. Brazil Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 24. Brazil Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 25. Brazil Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 26. Argentina Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 27. Argentina Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 28. Argentina Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 29. Argentina Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 30. Rest of South America Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 31. Rest of South America Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 32. Rest of South America Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 33. Rest of South America Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 34. Asia Pacific Short Bowel Syndrome, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 36. Asia Pacific Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 37. Asia Pacific Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 38. Asia Pacific Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 39. China Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 40. China Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 41. China Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 42. China Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 43. Japan Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 44. Japan Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 45. Japan Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 46. Japan Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 47. India Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 48. India Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 49. India Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 50. India Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 51. South Korea Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 52. South Korea Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 53. South Korea Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 54. South Korea Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 55. Taiwan Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 56. Taiwan Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 57. Taiwan Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 58. Taiwan Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 59. Australia Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 60. Australia Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 61. Australia Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 62. Australia Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 67. Europe Short Bowel Syndrome, by Country USD Million (2018-2023)
  • Table 68. Europe Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 69. Europe Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 70. Europe Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 71. Europe Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 72. Germany Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 73. Germany Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 74. Germany Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 75. Germany Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 76. France Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 77. France Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 78. France Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 79. France Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 80. Italy Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 81. Italy Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 82. Italy Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 83. Italy Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 84. United Kingdom Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 85. United Kingdom Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 86. United Kingdom Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 87. United Kingdom Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 88. Netherlands Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 89. Netherlands Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 90. Netherlands Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 91. Netherlands Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 92. Rest of Europe Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 93. Rest of Europe Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 94. Rest of Europe Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 95. Rest of Europe Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 96. MEA Short Bowel Syndrome, by Country USD Million (2018-2023)
  • Table 97. MEA Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 98. MEA Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 99. MEA Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 100. MEA Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 101. Middle East Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 102. Middle East Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 103. Middle East Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 104. Middle East Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 105. Africa Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 106. Africa Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 107. Africa Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 108. Africa Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 109. North America Short Bowel Syndrome, by Country USD Million (2018-2023)
  • Table 110. North America Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 111. North America Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 112. North America Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 113. North America Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 114. United States Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 115. United States Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 116. United States Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 117. United States Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 118. Canada Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 119. Canada Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 120. Canada Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 121. Canada Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 122. Mexico Short Bowel Syndrome, by Type USD Million (2018-2023)
  • Table 123. Mexico Short Bowel Syndrome, by Application USD Million (2018-2023)
  • Table 124. Mexico Short Bowel Syndrome, by Distribution Channel USD Million (2018-2023)
  • Table 125. Mexico Short Bowel Syndrome, by Patients USD Million (2018-2023)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Short Bowel Syndrome: by Type(USD Million)
  • Table 136. Short Bowel Syndrome GLP-2 , by Region USD Million (2024-2029)
  • Table 137. Short Bowel Syndrome Growth Hormone , by Region USD Million (2024-2029)
  • Table 138. Short Bowel Syndrome Glutamine , by Region USD Million (2024-2029)
  • Table 139. Short Bowel Syndrome Others , by Region USD Million (2024-2029)
  • Table 140. Short Bowel Syndrome: by Application(USD Million)
  • Table 141. Short Bowel Syndrome Hospitals , by Region USD Million (2024-2029)
  • Table 142. Short Bowel Syndrome Clinics , by Region USD Million (2024-2029)
  • Table 143. Short Bowel Syndrome: by Distribution Channel(USD Million)
  • Table 144. Short Bowel Syndrome Hospital Pharmacies , by Region USD Million (2024-2029)
  • Table 145. Short Bowel Syndrome Specialty Pharmacies , by Region USD Million (2024-2029)
  • Table 146. Short Bowel Syndrome Others , by Region USD Million (2024-2029)
  • Table 147. Short Bowel Syndrome: by Patients(USD Million)
  • Table 148. Short Bowel Syndrome Adults , by Region USD Million (2024-2029)
  • Table 149. Short Bowel Syndrome Kids , by Region USD Million (2024-2029)
  • Table 150. Short Bowel Syndrome Geriatric , by Region USD Million (2024-2029)
  • Table 151. South America Short Bowel Syndrome, by Country USD Million (2024-2029)
  • Table 152. South America Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 153. South America Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 154. South America Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 155. South America Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 156. Brazil Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 157. Brazil Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 158. Brazil Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 159. Brazil Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 160. Argentina Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 161. Argentina Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 162. Argentina Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 163. Argentina Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 164. Rest of South America Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 165. Rest of South America Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 166. Rest of South America Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 167. Rest of South America Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 168. Asia Pacific Short Bowel Syndrome, by Country USD Million (2024-2029)
  • Table 169. Asia Pacific Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 170. Asia Pacific Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 171. Asia Pacific Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 172. Asia Pacific Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 173. China Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 174. China Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 175. China Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 176. China Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 177. Japan Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 178. Japan Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 179. Japan Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 180. Japan Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 181. India Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 182. India Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 183. India Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 184. India Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 185. South Korea Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 186. South Korea Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 187. South Korea Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 188. South Korea Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 189. Taiwan Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 190. Taiwan Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 191. Taiwan Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 192. Taiwan Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 193. Australia Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 194. Australia Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 195. Australia Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 196. Australia Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 197. Rest of Asia-Pacific Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 198. Rest of Asia-Pacific Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 199. Rest of Asia-Pacific Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 200. Rest of Asia-Pacific Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 201. Europe Short Bowel Syndrome, by Country USD Million (2024-2029)
  • Table 202. Europe Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 203. Europe Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 204. Europe Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 205. Europe Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 206. Germany Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 207. Germany Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 208. Germany Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 209. Germany Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 210. France Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 211. France Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 212. France Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 213. France Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 214. Italy Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 215. Italy Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 216. Italy Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 217. Italy Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 218. United Kingdom Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 219. United Kingdom Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 220. United Kingdom Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 221. United Kingdom Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 222. Netherlands Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 223. Netherlands Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 224. Netherlands Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 225. Netherlands Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 226. Rest of Europe Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 227. Rest of Europe Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 228. Rest of Europe Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 229. Rest of Europe Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 230. MEA Short Bowel Syndrome, by Country USD Million (2024-2029)
  • Table 231. MEA Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 232. MEA Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 233. MEA Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 234. MEA Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 235. Middle East Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 236. Middle East Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 237. Middle East Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 238. Middle East Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 239. Africa Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 240. Africa Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 241. Africa Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 242. Africa Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 243. North America Short Bowel Syndrome, by Country USD Million (2024-2029)
  • Table 244. North America Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 245. North America Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 246. North America Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 247. North America Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 248. United States Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 249. United States Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 250. United States Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 251. United States Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 252. Canada Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 253. Canada Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 254. Canada Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 255. Canada Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 256. Mexico Short Bowel Syndrome, by Type USD Million (2024-2029)
  • Table 257. Mexico Short Bowel Syndrome, by Application USD Million (2024-2029)
  • Table 258. Mexico Short Bowel Syndrome, by Distribution Channel USD Million (2024-2029)
  • Table 259. Mexico Short Bowel Syndrome, by Patients USD Million (2024-2029)
  • Table 260. Research Programs/Design for This Report
  • Table 261. Key Data Information from Secondary Sources
  • Table 262. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Short Bowel Syndrome: by Type USD Million (2018-2023)
  • Figure 5. Global Short Bowel Syndrome: by Application USD Million (2018-2023)
  • Figure 6. Global Short Bowel Syndrome: by Distribution Channel USD Million (2018-2023)
  • Figure 7. Global Short Bowel Syndrome: by Patients USD Million (2018-2023)
  • Figure 8. South America Short Bowel Syndrome Share (%), by Country
  • Figure 9. Asia Pacific Short Bowel Syndrome Share (%), by Country
  • Figure 10. Europe Short Bowel Syndrome Share (%), by Country
  • Figure 11. MEA Short Bowel Syndrome Share (%), by Country
  • Figure 12. North America Short Bowel Syndrome Share (%), by Country
  • Figure 13. Global Short Bowel Syndrome share by Players 2023 (%)
  • Figure 14. Global Short Bowel Syndrome share by Players (Top 3) 2023(%)
  • Figure 15. Global Short Bowel Syndrome share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Shire Plc (United States) Revenue, Net Income and Gross profit
  • Figure 18. Shire Plc (United States) Revenue: by Geography 2023
  • Figure 19. Merck & Company, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Merck & Company, Inc. (United States) Revenue: by Geography 2023
  • Figure 21. Swedish Orphan Biovitrum AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 22. Swedish Orphan Biovitrum AB (Sweden) Revenue: by Geography 2023
  • Figure 23. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 25. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 27. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 28. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 29. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Mylan N.V. (United States) Revenue: by Geography 2023
  • Figure 31. AstraZeneca Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. AstraZeneca Plc (United Kingdom) Revenue: by Geography 2023
  • Figure 33. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 34. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 35. Global Short Bowel Syndrome: by Type USD Million (2024-2029)
  • Figure 36. Global Short Bowel Syndrome: by Application USD Million (2024-2029)
  • Figure 37. Global Short Bowel Syndrome: by Distribution Channel USD Million (2024-2029)
  • Figure 38. Global Short Bowel Syndrome: by Patients USD Million (2024-2029)
  • Figure 39. South America Short Bowel Syndrome Share (%), by Country
  • Figure 40. Asia Pacific Short Bowel Syndrome Share (%), by Country
  • Figure 41. Europe Short Bowel Syndrome Share (%), by Country
  • Figure 42. MEA Short Bowel Syndrome Share (%), by Country
  • Figure 43. North America Short Bowel Syndrome Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Shire Plc (United States)
  • Merck & Company, Inc. (United States)
  • Swedish Orphan Biovitrum AB (Sweden)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Mylan N.V. (United States)
  • AstraZeneca Plc (United Kingdom)
  • Johnson & Johnson (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 206 Pages 93 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Short Bowel Syndrome Market Quantitative research analysis
Global Short Bowel Syndrome Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Shire Plc (United States), Merck & Company, Inc. (United States), Swedish Orphan Biovitrum AB (Sweden), Novartis AG (Switzerland), Pfizer Inc. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (United States), AstraZeneca Plc (United Kingdom) and Johnson & Johnson (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Adoption of The Treatment " is seen as one of major influencing trends for Short Bowel Syndrome Market during projected period 2023-2029.
The Short Bowel Syndrome market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Short Bowel Syndrome Market Report?

Have a Query? Click Here

Other Related Reports

Epilepsy Drugs Comprehensive Study by Type (Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa, Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089)), Appl...
$ 3750
Next Generation Antibody Therapeutics Comprehensive Study by Type (Antibody Drug Conjugates (ADCs), Bispecific Antibodies (BsAbs), Fc Engineered Antibodies, Antibody Fragments and Antibody-Like Prote...
$ 3650
Microsclerotherapy Treatment Comprehensive Study by Type (Sclerosants (Chromated Glycerin, Sodium Tetradecyl Sulfate, Polidocanol, Others), Micro-Needles, Graduated Compression Hosiery Supports, Othe...
$ 3450
Halitosis Treatment Comprehensive Study by Type (Pathological, Non-pathological), Application (Lungs, Liver, Respiratory, Systemic, Gastrointestinal, Others), Diagnostic Tests (Gas chromatography, Ha...
$ 3750
Circulating Tumor Cells (CTC) Comprehensive Study by Type (Ex-Vivo Positive Selection, In-Vivo Positive Selection, Negative Selection, Microchips & Single Spiral Micro Channel), Application (Tumorige...
$ 3450
Sleep Disorder Therapeutics Comprehensive Study by Type (Drugs (Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists, Others), Medical Devices) Players and ...
$ 3500